Arch Therapeutics Inc. to Present at the LD MICRO Invitational 2014 on June 4th
28 May 2014 - 11:00PM
Marketwired
Arch Therapeutics Inc. to Present at the LD MICRO Invitational 2014
on June 4th
WELLESLEY, MA--(Marketwired - May 28, 2014) - Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences
company and developer of the AC5 Surgical Hemostatic Device™, a
novel product aimed at controlling bleeding and fluid loss in order
to provide faster and safer surgical and interventional care, is
pleased to announce that Company CEO, Terrence W. Norchi, MD, will
present at the LD MICRO Invitational on Wednesday, June 4th, 2014
in Los Angeles, CA.
At the LD MICRO Invitational Conference to be held at the Luxe
Hotel Sunset Boulevard in Los Angeles on Wednesday, June 4, Dr.
Norchi will present at 9:30 am PT (Track 3). The presentation will
be available via a live webcast, which can be accessed here:
http://wsw.com/webcast/ldmicro6/arth. This webcast will be archived
for 90 days following the live presentation.
"We are honored to have Arch present at our 4th annual
Invitational," stated Chris Lahiji, President of LD MICRO.
The LD MICRO Invitational has steadily grown each year since its
inception in 2010. This year the LD MICRO will be hosting over 80
micro-cap growth companies presenting throughout the day and is
expecting over 500 people to attend the event.
About Arch Therapeutics, Inc. Arch Therapeutics, Inc. is a
medical device company developing a novel approach to stop bleeding
(hemostasis) and control leaking (sealant) during surgery and
trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5 Surgical
Hemostatic Device™, is being designed to achieve hemostasis in
minimally invasive and open surgical procedures.
Find out more at www.archtherapeutics.com.
About LD MICRO LD MICRO is an investment newsletter firm that
focuses on finding undervalued companies in the micro-cap space.
Since 2002, the firm has published an annual list of recommended
stocks, as well as comprehensive reports on select companies
throughout the year. The firm also hosts the LD MICRO Micro-Cap
Growth Conference for investors in December of each year. It is a
non-registered investment advisor. For more information, please
contact 408-457-1042 or visit www.ldmicro.com.
Notice Regarding Forward-Looking Statements This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and
Section 21(e) of the Securities Exchange Act of 1934, as amended.
Statements in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Such forward-looking statements include, among other things,
references to novel technologies and methods, our business and
product development plans and projections, or market information.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with
developing new products or technologies and operating as a
development stage company, our ability to retain important members
of our management team and attract other qualified personnel, our
ability to raise the additional funding we will need to continue to
pursue our business and product development plans, our ability to
develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements
are made as of the date of this news release, and we assume no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Although we believe that any
beliefs, plans, expectations and intentions contained in this press
release are reasonable, there can be no assurance that any such
beliefs, plans, expectations or intentions will prove to be
accurate. Investors should consult all of the information set forth
herein and should also refer to the risk factors disclosure
outlined in the reports and other documents we file with the SEC,
available at www.sec.gov.
On Behalf of the Board, Terrence W. Norchi, MD Arch
Therapeutics, Inc.
Contact: ARTH Investor Relations Toll Free: +1-855-340-ARTH
(2784) (US and Canada) Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Dec 2023 to Dec 2024
